A Phase 3 Efficacy Study Of Dimebon In Patients With Moderate To Severe Alzheimer's Disease

Mise à jour : Il y a 4 ans
Référence : NCT00912288

Femme et Homme

Extrait

No Dimebon clinical data exist yet in patients with disease that has advanced to the moderate-to-severe stage. Therefore, this study evaluates the safety and efficacy of Dimebon in patients with moderate-to-severe AD who are receiving existing background therapy with memantine.


Critère d'inclusion

  • Alzheimer Disease


Liens